Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase NA 3Phase 1/2 3Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Syndrome, Transient 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Chromosome 5q Deletion Syndrome 1

Interventions

Imatinib Mesylate 28nilotinib 21Cytarabine 21Methotrexate 16Hydroxyurea 15Cyclophosphamide 15Busulfan 15Peripheral Blood Stem Cell Transplantation 13ruxolitinib 11Etoposide 11Whole-Body Irradiation 10fludarabine phosphate 9fludarabine 9Tacrolimus 9Mycophenolic Acid 9Daunorubicin 9Idarubicin 8Radiotherapy 7Mitoxantrone 7Interferon-alpha 7Cyclosporine 6peginterferon alfa-2a 5bosutinib 5asciminib 5Melphalan 5Azacitidine 5merphos 4luspatercept 4Thioguanine 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Flow Cytometry × Myeloid × Clear all
NCT00322101 2014-10-31

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Fred Hutchinson Cancer Center

Phase 3 Completed
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Myeloproliferative Syndrome, Transient, Congenital Abnormalities, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡